Max Mercado, MD
Internal Medicine · Philadelphia, PANPI 1336151182
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.9%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by AbbVie at 41.4% of the total. Reporting peaked in 2021 at $13,339 and has fallen 76.7% since, to $3,104 in 2025. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,515 payments — averaging $34.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$22K
- AstraZeneca$5K
- Novo Nordisk$4K
- Alnylam Pharmaceuticals Inc.$2K
- Modernatx, Inc.$2K
- Lilly USA, LLC$2K
- plus $16K from 54 others
Across 102 payments — averaging $5028.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$239K
- Modernatx, Inc.$69K
- Novartis$67K
- Currax Pharmaceuticals LLC$64K
- AstraZeneca$63K
- Exact Sciences$11K
What the payments were for
- Consulting fees$5,41010%
- Speaking & faculty fees$16,96433%
- Travel & lodging$5,11210%
- Food & beverage$24,38947%
- Education$960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,971 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 538 | $546,068 |
| EliquisApixaban | 313 | $310,881 |
| MounjaroTirzepatide | 191 | $214,584 |
| TrulicityDulaglutide | 203 | $212,384 |
| LinzessLinaclotide | 261 | $165,195 |
| FarxigaDapagliflozin Propanediol | 181 | $145,615 |
| RybelsusSemaglutide | 111 | $143,472 |
| JardianceEmpagliflozin | 167 | $132,508 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 202 | $128,439 |
| Xigduo XrDapaglifloz Propaned/Metformin | 179 | $127,514 |
| Tresiba Flextouch U-200Insulin Degludec | 149 | $104,797 |
| VraylarCariprazine Hcl | 65 | $87,074 |
| EntrestoSacubitril/Valsartan | 92 | $86,816 |
| JanuviaSitagliptin Phosphate | 124 | $86,145 |
| XareltoRivaroxaban | 64 | $73,617 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $3,738 | $740,762695 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,784 | $426,968394 claims |
| PfizerEliquis | $871 | $310,881313 claims |
| AbbVieLinzess, Vraylar, Qulipta, Namzaric | $21,518 | $286,181359 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Synjardy Xr | $773 | $227,496294 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,706 | $195,274364 claims |
| AstraZenecaFarxiga | $4,875 | $145,615181 claims |
| MerckJanuvia, Janumet Xr | $549 | $124,832180 claims |
| NovartisEntresto | $540 | $86,81692 claims |
| Johnson & JohnsonXarelto | $614 | $73,61764 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $219 | $54,717125 claims |
| AmgenProlia | $1,150 | $45,78629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Philadelphia
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- David GoldmannPhiladelphia$525K
- Eyob FeyssaPhiladelphia$328K
- Emil AbramianPhiladelphia$199K
- Michael KnightPhiladelphia$178K
- James BlakePhiladelphia$164K
- Gina SimonciniPhiladelphia$158K
- James LewisPhiladelphia$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.